In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections.

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. by Fritsche TR, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 201-209